Literature DB >> 10325924

The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

G Cox1, W P Steward, K J O'Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10325924      PMCID： PMC1745414          DOI： 10.1136/thx.54.2.169

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  197 in total

1.  Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma.

Authors:  I Takanami; F Tanaka; T Hashizume; S Kodaira
Journal:  Anticancer Res       Date:  1997 Jul-Aug       Impact factor: 2.480

2.  Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours.

Authors:  D Muller; R Breathnach; A Engelmann; R Millon; G Bronner; H Flesch; P Dumont; M Eber; J Abecassis
Journal:  Int J Cancer       Date:  1991-06-19       Impact factor: 7.396

Review 3.  Matrix metalloproteinase inhibitors.

Authors:  S M Wojtowicz-Praga; R B Dickson; M J Hawkins
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.

Authors:  T Oka; T Ishida; T Nishino; K Sugimachi
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

Review 5.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

6.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.

Authors:  G Giannelli; J Falk-Marzillier; O Schiraldi; W G Stetler-Stevenson; V Quaranta
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

7.  Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.

Authors:  J Mattern; R Koomägi; M Volm
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

8.  Hormonal regulation of matrix metalloproteinase inhibitors in rat granulosa cells and ovaries.

Authors:  J S Mann; M S Kindy; D R Edwards; T E Curry
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

9.  Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.

Authors:  A Meissauer; M D Kramer; M Hofmann; L J Erkell; E Jacob; V Schirrmacher; G Brunner
Journal:  Exp Cell Res       Date:  1991-02       Impact factor: 3.905

10.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).

Authors:  H Kobayashi; M Schmitt; L Goretzki; N Chucholowski; J Calvete; M Kramer; W A Günzler; F Jänicke; H Graeff
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157
View more
  10 in total

1.  A biological staging model for operable non-small cell lung cancer.

Authors:  G Cox; J L Jones; A Andi; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

2.  Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Authors:  Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 3.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

4.  A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.

Authors:  Xia Wang; Min Hou; Li Tan; Xinghui Sun; Yuqing Zhang; Ping Li; Yunsong Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-12       Impact factor: 4.553

5.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.

Authors:  Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

6.  Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.

Authors:  J Rollin; S Iochmann; C Bléchet; F Hubé; S Régina; S Guyétant; E Lemarié; P Reverdiau; Y Gruel
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

7.  Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.

Authors:  Chang Young Lee; Hyo Sup Shim; Seokkee Lee; Jin Gu Lee; Dae Joon Kim; Kyung Young Chung
Journal:  J Cardiothorac Surg       Date:  2015-03-27       Impact factor: 1.637

Review 8.  Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics.

Authors:  Gul-E-Saba Chaudhry; Abdah Md Akim; Yeong Yik Sung; Tengku Muhammad Tengku Sifzizul
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

9.  Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.

Authors:  J G Edwards; J McLaren; J L Jones; D A Waller; K J O'Byrne
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

10.  Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.

Authors:  Chia-Yi Su; Yu-Peng Liu; Chih-Jen Yang; Yuan-Feng Lin; Jean Chiou; Li-Hsing Chi; Jih-Jong Lee; Alex T H Wu; Pei-Jung Lu; Ming-Shyan Huang; Michael Hsiao
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.